News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Successful Phase One Demonstrates Tumor Response With Increased Overall Survival for Lead VBL Therapeutics Compound in Cancer


5/16/2013 12:01:38 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel--(BUSINESS WIRE)--VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of Ph1 data for VB-111 in the journal of Clinical Cancer Research. The manuscript reports a first in man clinical trial of VB-111, VBL’s lead anti-angiogenic Virotherapy candidate, demonstrating its safety and tolerability in patients with advanced metastatic cancer at a single administration of up to 1x1013 Viral Particles (VPs). Notably, tumor response and superior overall survival were found in the 1x1013 VPs cohort compared to sub-therapeutic doses. The data confirm pre-clinical findings in animal models and validate VB-111's mechanism of action, resulting in a targeted expression of the FAS-chimera transgene selectively in tumor vasculature.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES